A Look At HCA Healthcare (HCA) Valuation After Strong Results Outlook And New US$10b Buyback Program

HCA Healthcare (HCA) drew fresh attention after releasing fourth quarter and full year 2025 results, reporting higher sales and net income alongside a 2026 profit outlook above analyst expectations, a new US$10b share buyback program, and an increased dividend.

See our latest analysis for HCA Healthcare.

The shares have been volatile around the earnings release, with a 1 day share price return of -1.77% taking the price to US$482.53, but a 7 day share price return of 3.47% and 90 day share price return of 4.97% sit alongside a 1 year total shareholder return of 45.29% and 5 year total shareholder return of 181.02%. This points to momentum that has been supported by HCA Healthcare’s 2026 profit outlook, ongoing network expansion and AI initiatives, plus the new US$10b buyback and higher dividend.

If the latest earnings and buyback have you looking across the sector, it could be a good time to see what else is happening among healthcare stocks.

With HCA trading at US$482.53 and an average analyst price target near US$526, alongside a large estimated intrinsic value gap, the key question is whether this signals an undervalued hospital leader or if the market is already pricing in future growth?

Most Popular Narrative: 1% Undervalued

HCA Healthcare’s most followed narrative points to a fair value of about $488.76 versus the last close at $482.53, which frames the current move after earnings in the context of a modest implied discount.

Recent research points to a mix of confidence and caution around HCA Healthcare, with price targets generally adjusted higher while risks around government programs and the hospital backdrop remain front of mind.

Bullish Takeaways

Read the complete narrative.

Want to see what sits behind that fair value uplift? The narrative leans on revenue expansion, steadier margins and a future earnings multiple that is not stretched. Curious which assumptions really move the dial in this model and how long the runway runs? The full narrative lays those numbers out.

Result: Fair Value of $488.76 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still clear swing factors here, including potential policy shifts around Medicaid and federal programs, as well as any sustained pressure on outpatient surgical volumes.

Find out about the key risks to this HCA Healthcare narrative.

Build Your Own HCA Healthcare Narrative

If you see the numbers differently, or if you prefer to test your own assumptions, you can create a custom HCA view in just a few minutes with Do it your way.

A great starting point for your HCA Healthcare research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about finding your next opportunity, do not stop at one company. Let the data work for you and see what else stands out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com